Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday

Immix Biopharma (NASDAQ:IMMX - Get Free Report) is anticipated to announce its earnings results on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

Immix Biopharma Trading Down 1.1 %

Shares of IMMX traded down $0.02 during trading hours on Friday, hitting $1.80. 34,323 shares of the stock traded hands, compared to its average volume of 134,659. Immix Biopharma has a 1-year low of $1.26 and a 1-year high of $3.35. The firm has a market capitalization of $49.51 million, a PE ratio of -2.12 and a beta of 0.26. The business has a fifty day moving average of $1.86 and a 200-day moving average of $1.86.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Monday, February 10th.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.